Awaiting development: Guidance and quality standards

Showing 61 to 70 of 332

Guidance and quality standards awaiting development
Title	Type
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]	Technology appraisal guidance
Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]	Technology appraisal guidance
Children and young people with disabilities and severe complex needs: integrated health and social care support	Quality standard
Clascoterone for treating acne vulgaris in people 12 years and over [ID6572]	Technology appraisal guidance
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]	Technology appraisal guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]	Technology appraisal guidance
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]	Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance